Flibanserin: Understanding Its Role in Treating Hypoactive Sexual Desire Disorder

Hypoactive Sexual Desire Disorder (HSDD) is a common condition characterized by a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity, causing significant distress. It affects a substantial number of premenopausal women, impacting quality of life and relationships. Existing treatment options for HSDD have historically been limited, often focusing on psychological interventions or off-label hormonal therapies with mixed results. This review aimed to clarify Flibanserin's specific place in the therapeutic landscape for premenopausal women with HSDD, evaluating its efficacy, safety, and mechanism of action.

The review confirmed that Flibanserin demonstrated modest but statistically significant improvements in key HSDD symptoms compared to placebo. Across the pooled trials, women treated with Flibanserin experienced an average increase of 0.5 to 1.0 additional satisfying sexual events (SSEs) per month over placebo by week 24. Sexual desire scores, measured by the Female Sexual Function Index (FSFI) desire domain, showed an average increase of 1.5 to 2.0 points from baseline, significantly higher than the 0.3-0.5 point increase in the placebo group (p<0.001). The most impactful finding was a consistent reduction in distress associated with low sexual desire, with Flibanserin users reporting a 0.8 to 1.2 point greater decrease on the Female Sexual Distress Scale-Revised (FSDS-R) compared to placebo (p<0.001). Common adverse events included dizziness (11.4% vs. 3.3% for placebo), somnolence (11.2% vs. 2.8%), and nausea (10.4% vs. 3.9%), with a notable risk of severe hypotension and syncope when consumed with alcohol.